ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

July 3, 2023

Primary Completion Date

September 18, 2025

Study Completion Date

September 18, 2025

Conditions
Generalized Anxiety Disorder
Interventions
DRUG

ENX-102

Selective GABA-A alpha2,3,5 positive allosteric modulator

DRUG

Placebo

Placebo

Trial Locations (32)

10314

Richmond Behavioral Associates, Staten Island

11235

SPRI Clinical Trials, LLC, Brooklyn

11516

Neurobehavioral Research, Cedarhurst

31405

CenExel iResearch, LLC, Savannah

32256

Clinical Neuroscience Solutions, Inc., Jacksonville

32751

Accel Research Sites Network - Maitland CRU, Maitland

32801

Clinical Neuroscience Solutions, Inc., Orlando

33803

Accel Research Sites Network - Lakeland CRU, Lakeland

34711

Vertex Clinical Research, Clermont

38119

Clinical Neuroscience Solutions, Inc., Memphis

39232

Precise Research Centres, Flowood

66210

Collective Medical Research, Overland Park

75093

Aim Trials, Plano

75231

FutureSearch Trials of Dallas, Dallas

76309

Grayline Research Center, Wichita Falls

77030

Baylor College of Medicine, Houston

78737

Austin Clinical Trials Partners, Austin

80209

Mountain View Clinical Research, Denver

84015

Alpine Research Organization, Clinton

85012

IMA Clinical Research Phoenix, Phoenix

89102

IMA Clinical Research, Las Vegas

90015

NRC Research Institute, Los Angeles

90712

Alliance Research, Long Beach

91403

California Neuroscience Research, LLC, Sherman Oaks

91786

Pacific Clinical Research Management Group, Upland

92056

Excell Research, Inc., Oceanside

92251

Sun Valley Research Center, Imperial

92374

Anderson Clinical Research, Redlands

92845

Collaborative Neuroscience Research, LLC (CNS), Garden Grove

94596

Sunwise Clinical Research, Walnut Creek

98201

Core Clinical Research, Everett

02131

Boston Clinical Trials, Boston

Sponsors
All Listed Sponsors
lead

Engrail Therapeutics INC

INDUSTRY

NCT05749055 - ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder | Biotech Hunter | Biotech Hunter